A department built around disease directions
Founded in 1952 by Shi Yuquan, the department records national clinical key-specialty status, international neurosurgical training roles and participation as a principal unit of the National Neurological Medical Center established in 2021. It is a neurosurgical service within Fudan University's Huashan Hospital, rather than a stand-alone brain-tumor hospital.
Its clinical directions include vascular disease, glioma, skull-base and pituitary surgery, spine and spinal cord, functional and pediatric neurosurgery, trauma and critical care. That breadth matters when a diagnosis overlaps specialties: the initial question should identify the particular problem and whether another team has already proposed an assessment or treatment.
The 2023 Fudan national specialty reputation list placed the hospital's neurosurgery at position 2. Treat that as a dated historical reference for the department as a whole. It does not rank glioma, vascular or pituitary work separately, and it says nothing about an individual surgeon's results.
Glioma work and the brain-function question
Glioma is listed as its own clinical direction, and the research around it is closely tied to brain function. Wu Jinsong, a professor, chief physician and doctoral supervisor, is recorded as neurosurgery research deputy, deputy of the Fudan neurosurgery institute, director of the brain-function laboratory and leader of the National Neurological Medical Center's glioma group. The official profile gives these roles without an appointment date, so treat them as the current checked record rather than a timeline.
The same person holding the glioma group and the brain-function laboratory is the detail worth noticing. It means the tumour program and the function-focused work sit under one research leadership, not two unrelated directors. For a patient, that suggests a question rather than a promise: when a glioma is discussed, what function-related information would the clinical team want to see, and how would it weigh that against the tumour findings? Describe any existing weakness, seizure history or speech change in your own words, and ask which of those details the reviewing clinicians consider relevant. A laboratory title does not make its director your treating doctor, and it does not confirm that a particular monitoring or surgical approach is available to you.
For a glioma enquiry, explain whether the unresolved question concerns an initial opinion, an earlier treatment proposal or assessment after previous care. Ask what the team can assess from existing records and how function-related considerations would enter its discussion. A laboratory's interests can explain the program's questions, but the clinicians must determine what is relevant to the individual case.
Cerebrovascular care and the moyamoya registry
Gu Yuxiang, professor, chief physician and doctoral supervisor, is recorded as a neurosurgery deputy. His clinical focus is described as cerebrovascular endovascular, microsurgical and hybrid work, together with stroke, and his research covers pathophysiology, artificial intelligence and an adult moyamoya multicentre registry and biobank. His hospital deputy party secretary and union chair roles are administrative and do not determine clinical eligibility.
A September 2026 report on the National Center's site records that a studio led by Gu was designated a Shanghai health-system Model Worker and Craftsman Innovation Studio. The same report describes clinical vascular, endovascular, microsurgical and hybrid work, a multimodal moyamoya approach, expert consensus and guideline involvement, AI research and training. It also notes a Shanghai Medical Science First Prize as first contributor, and Shanghai Science and Technology First Prize, Shanghai Youth May 4 and Shanghai Craftsman recognitions without individual award years. None of these honours predicts an individual outcome.
A separate September 2026 report on a neurosurgical academic forum held on 4–6 September records that Mao Ying's and Gu Yuxiang's teams discussed MAGIC-MT research on non-acute, subacute and chronic subdural haematoma published in the New England Journal of Medicine, with an imaging secondary analysis in Radiology. That is a research direction. It is not a recommendation that any reader undergo embolisation, and it does not establish device availability for a particular patient.
Pituitary tumours, endocrinology and the Cushing study
Pituitary and endoscopic surgery is a separate clinical direction. The hospital describes an integrated pituitary ward established in 2018, bringing neurosurgical and endocrine contributions together. Its named contributors include Zhao Yao and Wang Yongfei in neurosurgery, and Zhang Chaoyun and Ye Hongying in endocrinology. That combination is particularly relevant to an enquiry involving both a pituitary lesion and an endocrine diagnosis.
On 6 March 2026 the National Center reported an international retrospective longitudinal study in Lancet Diabetes and Endocrinology, led by Zhao, examining USP8 genotype, tumour size and recurrence after Cushing disease surgery. Zhao is last corresponding author, with Zhang Qilin, Cai Yixin, Liu Yuyu and Yao Boyuan as co-first authors; Wang Yongfei and Ma Zengyi contributed clinical and follow-up work, and Zhang Chaoyun and Ye Hongying endocrine input.
Read that as an observational research question about how genotype and tumour features relate to recurrence. It is not a universal testing or follow-up prescription, it cannot predict your own recurrence, and it makes no claim of improved outcome. If you have Cushing disease, the useful questions are whether your pathology and biochemical results would be reviewed jointly by neurosurgery and endocrinology, and what each specialty would need to see.
Leadership, roles and what a title does and does not mean
Mao Ying has been hospital president since July 2020 and is a professor, doctoral supervisor and neurosurgery chief physician, recorded as neurosurgery executive deputy. His clinical and applied basic research covers brain tumours and cerebrovascular disease. His recognitions include Changjiang Distinguished Professor, National Distinguished Young Scholar and a national innovation leading talent designation, plus Shanghai Medical Development Outstanding Contribution, Young Science Outstanding Contribution and Wu Jieping Medical Innovation recognitions, and National Science and Technology Progress Second Prizes in different contributor roles.
A hospital president, clinical deputy and laboratory director have different responsibilities. A useful enquiry asks which group would assess the diagnosis, who would communicate its opinion and how follow-up responsibilities would be explained. The academic names above help distinguish programs; they do not confirm a personal appointment.
The department's institutional honours are also distinct from surgical outcomes. The 2018 Shanghai Quality Gold award and a 2021 national poverty-alleviation advanced collective designation belong to the institution, not to a procedure or a surgeon's results.
Practical decisions before you send records
State the established diagnosis, previous treatment and main unresolved decision. Ask which existing imaging, pathology or endocrine reports the relevant team requires, in what format, and what can be assessed before travel. Clarify how neurosurgical and other specialty input would be coordinated. The receiving hospital should confirm acceptance and proposed arrangements; urgent deterioration needs local care.
ChinaSpecialistCare can help prepare a neurosurgical enquiry, organise records and coordinate assessment arrangements after hospital acceptance. We are independent of Huashan Hospital and cannot guarantee a named clinician, operation or outcome. A brief initial enquiry is free and does not require purchasing an optional proxy consultation.
What the research reports add for a patient
The subdural-hematoma and Cushing reports investigate different problems: one concerns clinical and imaging features in vascular-neurosurgical research, the other genotype and recurrence in pituitary disease. They illustrate why an enquiry should identify the diagnosis rather than request a technique on the basis of a publication. Each research question belongs to a particular clinical setting.
A reasonable request is to ask whether any published work is relevant to your diagnosis and how the team weighs it. Ask also what is still uncertain. A clinician who can name the limits of the evidence is giving you more useful information than a confident promise, and it keeps the decision where it belongs: with the treating team and you.
Sources & scope of this guide
References and official service information relevant to this guide.
- Neurosurgery care in China
- Fudan 2023 historical national specialty reputation list
- Huashan Hospital official neurosurgery institutional and clinical overview
- Huashan Hospital official Mao Ying current leadership biography
- Huashan Hospital official Wu Jinsong professional profile
- Huashan National Neurological Medical Center official pituitary Cushing disease research2026
- Huashan Hospital official Gu Yuxiang current leadership biography
- Huashan National Neurological Medical Center official Gu Yuxiang innovation studio recognition2026
- Huashan National Neurological Medical Center official neurosurgical academic forum September2026
This is general planning information and has not been individually reviewed by a doctor. Medical decisions and personal treatment advice come from your treating clinicians.
